These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2957611)

  • 61. Antibodies to human caudate nucleus neurons in Huntington's chorea.
    Husby G; Li L; Davis LE; Wedege E; Kokmen E; Williams RC
    J Clin Invest; 1977 May; 59(5):922-32. PubMed ID: 140183
    [TBL] [Abstract][Full Text] [Related]  

  • 62. White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression.
    Novak MJ; Seunarine KK; Gibbard CR; Hobbs NZ; Scahill RI; Clark CA; Tabrizi SJ
    Cortex; 2014 Mar; 52():98-112. PubMed ID: 24405816
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated brain iron is independent from atrophy in Huntington's Disease.
    Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
    Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Presymptomatic testing for Huntington's disease.
    Bird SJ
    JAMA; 1985 Jun; 253(22):3286-91. PubMed ID: 3158756
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PET Imaging in Huntington's Disease.
    Roussakis AA; Piccini P
    J Huntingtons Dis; 2015; 4(4):287-96. PubMed ID: 26683130
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The FDG/PET methodology for early detection of disease onset: a statistical model.
    Clark CM; Ammann W; Martin WR; Ty P; Hayden MR
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):A96-102. PubMed ID: 1825496
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [A case report of late-onset Huntington disease without family history and caudate atrophy who has diagnosed clinicopathologically and genetically].
    Saito M; Ishikawa A; Iwanaga K; Igarashi S; Takahashi H; Tsuji S
    No To Shinkei; 1996 Oct; 48(10):949-53. PubMed ID: 8921535
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Huntington's disease: studies with structural imaging techniques and positron emission tomography.
    Mazziotta JC
    Semin Neurol; 1989 Dec; 9(4):360-9. PubMed ID: 2534934
    [No Abstract]   [Full Text] [Related]  

  • 69. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease.
    Mayberg HS; Starkstein SE; Peyser CE; Brandt J; Dannals RF; Folstein SE
    Neurology; 1992 Sep; 42(9):1791-7. PubMed ID: 1387463
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Use of polymorphous DNA probes in the study of French families with Huntington's chorea].
    Lucotte G; Berriche S; Burckel A; Turpin JC
    Rev Neurol (Paris); 1990; 146(4):303-5. PubMed ID: 1972803
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease.
    Kuwert T; Lange HW; Langen KJ; Herzog H; Aulich A; Feinendegen LE
    Psychiatry Res; 1989 Sep; 29(3):361-2. PubMed ID: 2532753
    [No Abstract]   [Full Text] [Related]  

  • 72. Radiosensitivity in Huntington's disease: implications for pathogenesis and presymptomatic diagnosis.
    Moshell AN; Tarone RE; Barrett SF; Robbins JH
    Lancet; 1980 Jan; 1(8158):9-11. PubMed ID: 6101401
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Exclusion testing for Huntington's disease in pregnancy with a closely linked DNA marker.
    Quarrell OW; Meredith AL; Tyler A; Youngman S; Upadhyaya M; Harper PS
    Lancet; 1987 Jun; 1(8545):1281-3. PubMed ID: 2884411
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease.
    Vittori A; Breda C; Repici M; Orth M; Roos RA; Outeiro TF; Giorgini F; Hollox EJ;
    Hum Mol Genet; 2014 Jun; 23(12):3129-37. PubMed ID: 24452335
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?
    Shin H; Kim MH; Lee SJ; Lee KH; Kim MJ; Kim JS; Cho JW
    J Clin Neurol; 2013 Jan; 9(1):21-5. PubMed ID: 23346156
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Seeking brain biomarkers for preventive therapy in Huntington disease.
    Esmaeilzadeh M; Ciarmiello A; Squitieri F
    CNS Neurosci Ther; 2011 Oct; 17(5):368-86. PubMed ID: 20553306
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Functional imaging in Huntington's disease.
    Paulsen JS
    Exp Neurol; 2009 Apr; 216(2):272-7. PubMed ID: 19171138
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Positron emission tomography imaging of transplant function.
    Brooks DJ
    NeuroRx; 2004 Oct; 1(4):482-91. PubMed ID: 15717049
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.